<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Febris Therapeutics - AI-Driven Therapeutics for Antibiotic-Resistant Infections and Sepsis">
    <meta name="keywords" content="antibiotic resistance, AI drug discovery, sepsis, bacterial therapeutics, gonorrhea, novel antibiotics">
    <title>Febris Therapeutics - AI-Driven Therapeutics for Antibiotic Resistance & Sepsis</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            line-height: 1.6;
            color: #333;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
        }

        .container {
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
        }

        .card {
            background: white;
            border-radius: 12px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.2);
            padding: 40px;
            margin: 20px 0;
        }

        header {
            text-align: center;
            padding: 60px 0 40px;
            color: white;
        }

        h1 {
            font-size: 3em;
            margin-bottom: 10px;
            font-weight: 700;
            letter-spacing: -1px;
        }

        .tagline {
            font-size: 1.3em;
            font-weight: 300;
            margin-bottom: 30px;
            opacity: 0.95;
        }

        h2 {
            color: #667eea;
            font-size: 1.8em;
            margin: 30px 0 15px 0;
            border-bottom: 3px solid #667eea;
            padding-bottom: 10px;
        }

        h3 {
            color: #764ba2;
            font-size: 1.3em;
            margin: 20px 0 10px 0;
        }

        p {
            margin: 15px 0;
            font-size: 1.05em;
            line-height: 1.7;
        }

        ul {
            margin: 15px 0 15px 30px;
        }

        li {
            margin: 8px 0;
            line-height: 1.6;
        }

        .highlight {
            background: linear-gradient(120deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 30px;
            border-radius: 8px;
            margin: 30px 0;
        }

        .highlight h2 {
            color: white;
            border-color: rgba(255,255,255,0.3);
        }

        .stats {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .stat-box {
            background: #f8f9fa;
            padding: 20px;
            border-radius: 8px;
            text-align: center;
            border-left: 4px solid #667eea;
        }

        .stat-number {
            font-size: 2.5em;
            font-weight: bold;
            color: #667eea;
        }

        .stat-label {
            color: #666;
            font-size: 0.9em;
            margin-top: 5px;
        }

        .contact {
            text-align: center;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 8px;
            margin-top: 30px;
        }

        .contact a {
            color: #667eea;
            text-decoration: none;
            font-weight: 600;
            font-size: 1.2em;
        }

        .contact a:hover {
            text-decoration: underline;
        }

        footer {
            text-align: center;
            padding: 30px;
            color: white;
            font-size: 0.9em;
        }

        .badge {
            display: inline-block;
            background: #667eea;
            color: white;
            padding: 5px 15px;
            border-radius: 20px;
            font-size: 0.85em;
            margin: 5px;
            font-weight: 600;
        }

        @media (max-width: 768px) {
            h1 {
                font-size: 2em;
            }

            .tagline {
                font-size: 1.1em;
            }

            .card {
                padding: 25px;
            }

            .stats {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <header>
        <div class="container">
            <h1>FEBRIS THERAPEUTICS</h1>
            <p class="tagline">AI-Driven Therapeutics for Antibiotic-Resistant Infections & Sepsis</p>
        </div>
    </header>

    <div class="container">
        <div class="card">
            <h2>The Challenge</h2>
            <p>Antibiotic resistance is one of the greatest threats to global health. The World Health Organization has identified <strong>critical priority pathogens</strong> including <em>Neisseria gonorrhoeae</em>, <em>Acinetobacter baumannii</em>, and <em>Pseudomonas aeruginosa</em> that urgently need new treatments.</p>

            <div class="stats">
                <div class="stat-box">
                    <div class="stat-number">700K+</div>
                    <div class="stat-label">Annual deaths from drug-resistant infections</div>
                </div>
                <div class="stat-box">
                    <div class="stat-number">11M</div>
                    <div class="stat-label">Annual deaths from sepsis worldwide</div>
                </div>
                <div class="stat-box">
                    <div class="stat-number">$100B</div>
                    <div class="stat-label">Global antibiotic market by 2030</div>
                </div>
                <div class="stat-box">
                    <div class="stat-number">$62B</div>
                    <div class="stat-label">Annual US healthcare costs from sepsis</div>
                </div>
            </div>
        </div>

        <div class="card highlight">
            <h2>Our Solution</h2>
            <p>Febris Therapeutics is developing <strong>AI-designed therapeutics</strong> targeting novel essential bacterial proteins involved in outer membrane assembly—critical machinery present in all Gram-negative bacteria. Our proprietary platform addresses both bacterial infection and the sepsis cascade.</p>

            <h3>Dual Mechanism of Action</h3>
            <ul>
                <li><strong>Direct bacterial inhibition:</strong> Targets essential proteins required for bacterial survival</li>
                <li><strong>Sepsis cascade interruption:</strong> Prevents lipopolysaccharide (LPS) release and downstream inflammatory response</li>
                <li><strong>Pan-bacterial activity:</strong> Conserved target across multiple Gram-negative pathogens</li>
                <li><strong>Resistance-proof design:</strong> Targeting essential machinery limits resistance development</li>
            </ul>

            <h3>Why Our Target?</h3>
            <ul>
                <li><strong>Essential for survival:</strong> Required for bacterial outer membrane assembly and viability</li>
                <li><strong>Validated druggability:</strong> Multiple inhibitor classes confirm target is accessible and drug-responsive</li>
                <li><strong>Sepsis prevention:</strong> Target inhibition reduces LPS release, blocking the sepsis cascade at its source</li>
                <li><strong>Broad-spectrum potential:</strong> Highly conserved across all Gram-negative bacteria</li>
            </ul>
        </div>

        <div class="card">
            <h2>Sepsis Prevention: A Critical Unmet Need</h2>

            <p>Sepsis—the body's overwhelming inflammatory response to infection—kills <strong>11 million people annually</strong> and costs the US healthcare system <strong>$62 billion per year</strong>. Despite decades of research, no effective sepsis therapeutics exist that target the root cause.</p>

            <h3>The LPS-Sepsis Connection</h3>
            <p>Gram-negative bacterial infections trigger sepsis through the release of lipopolysaccharide (LPS), also known as endotoxin. When bacteria die—whether from natural causes or antibiotic treatment—they release massive amounts of LPS, triggering a cytokine storm that leads to:</p>
            <ul>
                <li>Systemic inflammation and multi-organ failure</li>
                <li>Septic shock and cardiovascular collapse</li>
                <li>30-50% mortality rate despite intensive care</li>
                <li>$62B annual healthcare costs in the US alone</li>
            </ul>

            <h3>Our Approach: Prevention at the Source</h3>
            <p>Rather than treating sepsis after it develops, our therapeutics <strong>prevent LPS release</strong> by targeting essential outer membrane assembly proteins. By inhibiting this critical bacterial machinery:</p>
            <ul>
                <li>✅ <strong>Bacteria are killed</strong> without lysing (controlled cell death)</li>
                <li>✅ <strong>LPS remains sequestered</strong> within dying bacteria</li>
                <li>✅ <strong>Sepsis cascade is prevented</strong> before it starts</li>
                <li>✅ <strong>Dual benefit:</strong> Antibacterial effect + sepsis prevention in one therapeutic</li>
            </ul>

            <p><strong>Market Impact:</strong> This dual mechanism positions our therapeutics uniquely for both antibiotic-resistant infections ($100B market) and sepsis prevention ($4.2B market growing to $8.6B by 2030).</p>
        </div>

        <div class="card">
            <h2>Technology Platform</h2>

            <h3>AI-Powered Drug Discovery</h3>
            <p>Our proprietary approach combines artificial intelligence with computational molecular docking to design and validate novel therapeutics with unprecedented speed and accuracy.</p>

            <div style="margin: 20px 0;">
                <span class="badge">AI Sequence Generation</span>
                <span class="badge">Computational Docking</span>
                <span class="badge">Structure-Based Design</span>
                <span class="badge">Multi-Species Validation</span>
            </div>

            <h3>Our Therapeutic Approach</h3>
            <p>Febris Therapeutics employs a proprietary class of therapeutics designed to bind bacterial targets with high affinity and specificity. Our platform offers significant advantages over traditional antibiotics:</p>
            <ul>
                <li><strong>Rapid development:</strong> AI-accelerated design reduces development time from years to months</li>
                <li><strong>Low toxicity profile:</strong> Selective targeting minimizes off-target effects</li>
                <li><strong>Scalable manufacturing:</strong> Chemical synthesis enables reproducible, cost-effective production</li>
                <li><strong>Stability:</strong> Robust formulation suitable for diverse clinical settings</li>
                <li><strong>Resistance-proof design:</strong> Targets essential protein structures with low mutation tolerance</li>
                <li><strong>Dual benefit:</strong> Direct antibacterial effect plus sepsis cascade prevention</li>
            </ul>
        </div>

        <div class="card">
            <h2>Pipeline & Development</h2>

            <h3>Lead Program: Gonorrhea + Sepsis Prevention</h3>
            <p><strong>Primary Indication:</strong> Antibiotic-resistant <em>Neisseria gonorrhoeae</em> (gonorrhea)</p>
            <p><strong>Secondary Benefit:</strong> Sepsis prevention through LPS neutralization</p>

            <p><strong>Stage:</strong> Computational validation complete, advancing to experimental validation</p>

            <p><strong>Preclinical Validation:</strong></p>
            <ul>
                <li>Validated against <strong>4 WHO priority pathogens</strong> (N. gonorrhoeae, A. baumannii, P. aeruginosa, E. coli)</li>
                <li>Superior predicted binding to N. gonorrhoeae target protein</li>
                <li>Pan-bacterial activity demonstrated across multiple Gram-negative species</li>
                <li>Targets conserved structural features of essential outer membrane machinery</li>
                <li>Expected to reduce LPS release and subsequent inflammatory cascade</li>
            </ul>

            <h3>Platform Potential</h3>
            <p>Our technology platform enables rapid development of therapeutics against multiple bacterial targets with built-in sepsis prevention:</p>
            <ul>
                <li><strong>Lead program:</strong> N. gonorrhoeae (STI market $2.4B + sepsis prevention)</li>
                <li><strong>Hospital-acquired infections:</strong> A. baumannii, P. aeruginosa (biodefense + ICU sepsis prevention)</li>
                <li><strong>Cystic fibrosis:</strong> P. aeruginosa chronic infections with reduced inflammatory burden</li>
                <li><strong>Sepsis therapeutics:</strong> Preventive treatment for high-risk surgical and ICU patients</li>
                <li><strong>Platform expansion:</strong> Additional Gram-negative pathogens and sepsis indications</li>
            </ul>
        </div>

        <div class="card highlight">
            <h2>Key Milestones</h2>
            <ul>
                <li><strong>2026 Q1:</strong> Computational validation complete (4 WHO pathogens)</li>
                <li><strong>2026 Q2:</strong> Experimental validation (binding assays, Kd determination)</li>
                <li><strong>2026 Q3-Q4:</strong> Lead optimization & antibacterial activity testing</li>
                <li><strong>2027:</strong> IND-enabling studies</li>
            </ul>
        </div>

        <div class="card">
            <h2>Funding & Partnerships</h2>
            <p>We are actively seeking:</p>
            <ul>
                <li><strong>NIH SBIR grants</strong> (Phase I: $300-400K)</li>
                <li><strong>DoD SBIR grants</strong> (biodefense applications)</li>
                <li><strong>Strategic partnerships</strong> with pharmaceutical companies</li>
                <li><strong>Technology partnerships</strong> with AI/cloud providers (NVIDIA, Microsoft, Google, AWS)</li>
                <li><strong>Angel/seed investment</strong> for experimental validation</li>
            </ul>
        </div>

        <div class="card">
            <h2>Market Opportunity</h2>

            <h3>Target Markets</h3>
            <ul>
                <li><strong>Antibiotic resistance:</strong> $100B+ global market by 2030</li>
                <li><strong>Sepsis therapeutics:</strong> $4.2B market growing to $8.6B by 2030</li>
                <li><strong>Gonorrhea treatment:</strong> $2.4B market (600K+ cases/year in US alone)</li>
                <li><strong>Hospital-acquired infections:</strong> $10B+ market (A. baumannii, P. aeruginosa)</li>
                <li><strong>Biodefense:</strong> Government procurement for critical pathogens and sepsis countermeasures</li>
            </ul>

            <h3>Competitive Advantages</h3>
            <ul>
                <li><strong>AI-driven speed:</strong> Months vs. years for traditional drug discovery</li>
                <li><strong>Dual mechanism:</strong> Direct antibacterial action PLUS sepsis cascade prevention</li>
                <li><strong>Novel target class:</strong> Essential outer membrane machinery (distinct from traditional antibiotics, reduces resistance)</li>
                <li><strong>Pan-bacterial platform:</strong> Single technology applicable to multiple WHO priority pathogens</li>
                <li><strong>De-risked development:</strong> Computational validation identifies lead candidates before costly experiments</li>
                <li><strong>Sepsis market entry:</strong> Addresses $4.2B unmet need with novel approach</li>
            </ul>
        </div>

        <div class="card">
            <h2>Team & Advisors</h2>
            <p>Febris Therapeutics is led by experienced professionals in biotechnology, computational biology, and drug development.</p>
            <p><em>Team details available upon request for qualified investors and partners.</em></p>
        </div>

        <div class="card contact">
            <h2>Contact Us</h2>
            <p>Interested in learning more about our technology or discussing partnership opportunities?</p>
            <p style="margin-top: 20px;">
                <a href="mailto:contact@febristherapeutics.com">contact@febristherapeutics.com</a>
            </p>
            <p style="margin-top: 30px; font-size: 0.9em; color: #666;">
                For investor inquiries, partnership opportunities, or media requests, please reach out via email.
            </p>
        </div>
    </div>

    <footer>
        <div class="container">
            <p>&copy; 2026 Febris Therapeutics. All rights reserved.</p>
            <p style="margin-top: 10px; opacity: 0.8;">Advancing the fight against antibiotic-resistant infections and sepsis through AI-driven innovation.</p>
        </div>
    </footer>
</body>
</html>
